Veracyte, Inc is a biotechnology business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 320 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Veracyte
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VCYT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Veracyte stock price (NASDAQ: VCYT)Use our graph to track the performance of VCYT stocks over time.
Veracyte shares at a glance
|Latest market close||$40.40|
|52-week range||$28.82 - $86.03|
|50-day moving average||$38.46|
|200-day moving average||$48.46|
|Wall St. target price||$65.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.29|
Buy Veracyte shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Veracyte stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Veracyte price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||0.90%|
|3 months (2021-04-30)||-18.79%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
|Revenue TTM||$123.1 million|
|Gross profit TTM||$77.1 million|
|Return on assets TTM||-3.03%|
|Return on equity TTM||-10.8%|
|Market capitalisation||$2.6 billion|
TTM: trailing 12 months
Shorting Veracyte shares
There are currently 3.9 million Veracyte shares held short by investors – that's known as Veracyte's "short interest". This figure is 9.6% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Veracyte shares can be evaluated.
Veracyte's "short interest ratio" (SIR)
Veracyte's "short interest ratio" (SIR) is the quantity of Veracyte shares currently shorted divided by the average quantity of Veracyte shares traded daily (recently around 796831.70731707). Veracyte's SIR currently stands at 4.92. In other words for every 100,000 Veracyte shares traded daily on the market, roughly 4920 shares are currently held short.
However Veracyte's short interest can also be evaluated against the total number of Veracyte shares, or, against the total number of tradable Veracyte shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veracyte's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Veracyte shares in existence, roughly 60 shares are currently held short) or 0.0587% of the tradable shares (for every 100,000 tradable Veracyte shares, roughly 59 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Veracyte.
Find out more about how you can short Veracyte stock.
Veracyte share dividends
We're not expecting Veracyte to pay a dividend over the next 12 months.
Veracyte share price volatility
Over the last 12 months, Veracyte's shares have ranged in value from as little as $28.82 up to $86.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 0.7318. This would suggest that Veracyte's shares are less volatile than average (for this exchange).
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc. ; and Bayer AG.
Stocks similar to Veracyte
Veracyte in the news
Veracyte, Inc. 2021 Q2 - Results - Earnings Call Presentation
Veracyte Stock Moves Higher As Q2 Earnings Surpass Expectations; Analysts Raise Price Target
41 Stocks Moving In Friday's Mid-Day Session
Frequently asked questionsWhat percentage of Veracyte is owned by insiders or institutions?
Currently 1.014% of Veracyte shares are held by insiders and 106.03% by institutions. How many people work for Veracyte?
Latest data suggests 320 work at Veracyte. When does the fiscal year end for Veracyte?
Veracyte's fiscal year ends in December. Where is Veracyte based?
Veracyte's address is: 6000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Veracyte's ISIN number?
Veracyte's international securities identification number is: US92337F1075 What is Veracyte's CUSIP number?
Veracyte's Committee on Uniform Securities Identification Procedures number is: 92337F107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert